| 초록 |
Objectives: Pre-transplant donor specific anti-HLA antibody (DSA) is associated with antibody mediated rejection (AMR). However, the impact of DSA-DQ has not been fully investigated yet. This study aims to investigate the clinical relevance of pre-transplant DSA-DQ compared to other types of DSA.
Methods: In this retrospective study, 1,110 KTRs who underwent ABO compatible kidney transplantation (KT) with available DQ typing between January 2010 and December 2019 were screened. Cases were divided into 3 groups according to the presence and the type of pre-transplant DSAs [no-DSA (n=1,008), non-DQ (n=84), and DQ (n=18)]. We compared the incidence of post-transplant AMR and graft survival, and described immunological characteristics of KTRs who had isolated pre-transplant DSA-DQ in detail.
Results: The MFI value of DSA-DQ after desensitization was higher than that of DSA-non-DQ. The incidence of 1-year AMR were significantly higher in the non-DQ and DQ groups than no-DSA group, but there was no difference between non-DQ and DQ groups (no-DSA vs. non-DQ, log rank p<0.001; no-DSA vs DQ, p<0.001; non-DQ vs DQ, p=0.836). The incidence of overall AMR and graft survival also showed no difference between non-DQ and DQ groups. Among 18 KTRs in DQ group, 3 showed persistent high MFI value of DSA-DQ during post-transplant period. However, only 1 patient who had C1q binding DSA-DQ developed AMR. Among 2 patients who developed AMR, even with lowering of DSA-DQ during post-transplant period, 1 had C1q binding activity before KT, and the other had de novo DSA-B13 antibody at AMR.
Conclusions: In patients with pre-transplant DSA DQ, the MFI value of DSA was higher compared to DSA-non-DQ even after desensitization. However, the incidence of AMR, and graft survival were similar. C1q binding activity could give impact on the development of AMR. Therefore, MFI value of DSA-DQ should not be a hurdle in proceeding with kidney transplantation.
|